Medical Devices DECODED
Previous edition: 16 May 2024
Share article
Get the full version straight to your inbox.
Exclusive access to our best-in-class data & intelligence
Subscribe now
Wondfo USA's Covid-19/Influenza Test receives FDA EUA approval
The authorisation allows healthcare providers to quickly distinguish between Covid-19 and influenza.
DCN Dx, a contract research organisation for in vitro diagnostics, has announced that Wondfo USA's WELLlife Covid-19/Influenza A&B Test received emergency use authorisation (EUA) from the US Food and Drug Administration (FDA).
Wondfo USA's collaboration with DCN Dx through the National Institutes of Health (NIH) Independent Test Assessment Program (ITAP) has led to the performance and clinical validation of the WELLlife test in the US.
DCN Dx chief operating officer Pat Vaughan said: “We extend our congratulations to the Wondfo USA team on achieving FDA EUA for the WELLlife test. Their dedication and expertise have culminated in a crucial tool that will positively impact healthcare.”
The authorisation allows healthcare providers to quickly distinguish between Covid-19 and influenza, improving patient outcomes at the point of care.
The test's rapid diagnostic capabilities are crucial for managing respiratory infections with similar symptoms.
DCN Dx said the NIH's Rapid Acceleration of Diagnostics (RADx) Tech programme and its ITAP have been instrumental in expediting the regulatory review and availability of high-quality diagnostic tests.
Wondfo USA's WELLlife test is designed to allow the qualitative detection and differentiation of influenzas A and B, as well as SARS-CoV-2, from anterior nasal samples.
The rapid diagnostic test is a critical tool for healthcare professionals to manage and treat respiratory virus infections, which often have overlapping clinical presentations.
DCN Dx clinical research vice-president Emily Friedland said: “Our role in the clinical research for the WELLlife test exemplifies our commitment to supporting the development and commercialisation of important diagnostics.
“We are proud to have supported Wondfo USA in the clinical research and validation stages that were crucial for achieving FDA EUA.”
Latest news
Atraverse receives approval for HOTWIRE Left Heart Access Device
The guidewire system is compatible with universal sheaths and features advanced RF technology.
GE HealthCare and Medis partner on non-invasive coronary assessments
The companies will integrate Medis Medical’s non-invasive coronary physiology test, Medis QFR, with GE HealthCare’s cardiology Allia Platform.
Butterfly Network launches iQ+ Bladder in US
The iQ+ Bladder leverages the company's Ultrasound-on-Chip technology to provide a comprehensive bladder scanning solution.
Labcorp launches first trimester preeclampsia screening test
The new screening test needs to be conducted between 11 and 14 weeks of gestation for early detection of preeclampsia risk.
Study finds intravascular imaging effective for imaging the brain
The study into Spryte Medical’s neuro Optical Coherence Tomography device found that it was effective at gathering evidence of strokes and other neurological conditions.
SPR Therapeutics reports positive data for PNS pain relief device
Cleveland based medical device company SPR Therapeutics announced a key milestone with the 10,000th patient treated using the SPRINT PNS System. The SPRINT System provides a low-risk alternative to opioids and does not require ablation, surgery, or permanent device implantation.
Boston Scientific on the importance of positive company culture at Cork facility
The medical device giant is consistently ranked as one of the top employers in Ireland but retaining skills and talent remains one of the company’s biggest challenges.
In our previous edition
Medical Devices Decoded
FDA issues recall notice for Philips after another respiratory device fails
15 May 2024
Medical Devices Decoded
FDA warns users not to use Cue Health's at-home Covid-19 tests
14 May 2024
Medical Devices Decoded
Dementia Action Week 2024: the future of Alzheimer's diagnostics
13 May 2024
Newsletters in other sectors
Aerospace, Defence & Security
Automotive
Banking & Payments
Medical Devices
Oil & Gas
Travel and Tourism
Search companies, themes, reports, as well as actionable data & insights spanning 22 global industries
Access more premium companies when you subscribe to Explorer